SCM
NBIX icon

Stevens Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Stevens Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,003
Closed -$231K – 357
2024
Q3 		$231K Buy
+2,003
New +$275K 0.03% 188
2020
Q1 		– Sell
-4,692
Closed -$504K – 280
2019
Q4 		$504K Buy
4,692
+659
+16% +$69K 0.05% 348
2019
Q3 		$363K Buy
+4,033
New +$377K 0.03% 422
2019
Q1 		– Sell
-3,572
Closed -$255K – 821
2018
Q4 		$255K Sell
3,572
-8,864
-71% -$849K 0.01% 594
2018
Q3 		$1.53M Buy
+12,436
New +$1.41M 0.06% 354
2018
Q2 		– Sell
-20,310
Closed -$1.68M – 914
2018
Q1 		$1.68M Buy
+20,310
New +$1.72M 0.06% 320
2017
Q2 		– Sell
-27,508
Closed -$1.19M – 988
2017
Q1 		$1.19M Buy
+27,508
New +$1.18M 0.05% 384
2016
Q4 		– Sell
-14,961
Closed -$758K – 1030
2016
Q3 		$758K Buy
+14,961
New +$745K 0.03% 485
2015
Q4 		– Sell
-12,189
Closed -$485K – 1059
2015
Q3 		$485K Buy
+12,189
New +$589K 0.02% 542
2014
Q3 		– Sell
-11,481
Closed -$170K – 1165
2014
Q2 		$170K Buy
+11,481
New +$162K ﹤0.01% 954
2014
Q1 		– Sell
-22,439
Closed -$210K – 1238
2013
Q4 		$210K Buy
+22,439
New +$219K 0.01% 898

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stevens Capital Management's NBIX Position: Q4 2024 in Review

Stevens Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 2,003 shares — an estimated $231K sold.

Stevens Capital Management first reported a position in NBIX in Q4 2013 and held it in 11 quarters. The position peaked at $1.68M in Q1 2018. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Stevens Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Stevens Capital Management sold 2,003 Neurocrine Biosciences shares in Q4 2024, an estimated $231K.
  • Stevens Capital Management first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 11 quarters.
  • Stevens Capital Management's Neurocrine Biosciences position peaked at $1.68M in Q1 2018.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Stevens Capital Management's 13F filing for Q4 2024, filed 11 Feb 2025.